Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple‐Negative Breast Cancer
Thoracic Cancer · 2025-05 · 16 (9)
DOI: 10.1111/1759-7714.70072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 05.05.2025. Verfasst von Xinran Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immune Checkpoint Inhibitors, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MSD China.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC), accounting for about 10%–20% of all breast cancer cases, is characterized by its aggressive nature, high recurrence rates, and poor prognosis. Unlike other breast cancer subtypes, TNBC lacks hormone receptors and specific molecular targets, limiting therapeutic options. In recent years, immune checkpoint inhibitors (ICIs) have shown promise in treating TNBC by targeting immune evasion mechanisms. Despite these advancements, several issues remain unresolved, including low response rates in programmed cell death ligand 1 (PD‐L1) negative TNBC subtypes and the challenge of predicting which patients will benefit from ICIs. Consequently, there is growing interest in identifying reliable biomarkers beyond PD‐L1 expression. This review synthesizes recent studies to provide a comprehensive perspective on ICI therapy in TNBC, clarifying the status of single‐agent ICI therapies and combination strategies, emphasizing the need for further research into biomarkers. These insights provide clues for more personalized and effective treatment approaches, ultimately aiming to improve clinical outcomes for patients with TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Value & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai, China.
ORCID-Profile: Lingxia Wang
Förderung
- MSD China
Zitieren
APA
Wang, X., Wang, L., & Liu, Y. (2025). Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple‐Negative Breast Cancer. Thoracic Cancer, 16(9). https://doi.org/10.1111/1759-7714.70072
Vancouver
Wang X, Wang L, Liu Y. Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple‐Negative Breast Cancer. Thoracic Cancer. 2025;16(9). doi:10.1111/1759-7714.70072
BibTeX
@article{Wang2025,
author = {Wang, Xinran and Wang, Lingxia and Liu, Yueping},
title = {Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple‐Negative Breast Cancer},
journal = {Thoracic Cancer},
year = {2025},
volume = {16},
number = {9},
doi = {10.1111/1759-7714.70072}
}
EUVIMED